Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Topics
  4. Financials
  5. Annual Results

Annual Results

Thumbnail
March 23, 2022

Breakeven still distant for Oxford Nanopore

Thumbnail
March 11, 2022

Another strike for biotech: China

Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.

Article image
Vantage logo
February 24, 2022

Biomarin’s Voxzogo disappoints in youngsters

Article image
Vantage logo
February 10, 2022

Astra bake-off cooks up a new inhaled Jak

Article image
Vantage logo
February 09, 2022

Pfizer’s $100bn question

Record guidance disappoints, so talk once again turns to deals.

Article image
Vantage logo
February 09, 2022

For Mirati Kras gives and it takes away

Article image
Vantage logo
February 03, 2022

A year of Tigit (and Alzheimer’s) for Roche

With four pivotal tiragolumab readouts, Roche’s 2022 will not only be the year of Alzheimer’s.

Article image
Vantage logo
February 06, 2020

Opdivo enters doomsday territory

Article image
Vantage logo
January 23, 2020

Abbott and J&J start the year from different places

Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.

Article image
Vantage logo
February 06, 2019

Glaxo adds flesh to its oncology ambitions

As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.

Article image
Vantage logo
January 30, 2019

Novartis hopes Kymriah acceleration can save its CAR

Despite manufacturing struggles, Novartis still expects Kymriah to become a blockbuster.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.